European consensus on the histopathology of inflammatory bowel disease
…, PB Nunes, G Cathomas, W Fries… - Journal of Crohn's …, 2013 - academic.oup.com
The histologic examination of endoscopic biopsies or resection specimens remains a key
step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for …
step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for …
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre …
…, R Fogel, J Fon, M Frankel, K Friedenberg, W Fries… - The Lancet, 2022 - thelancet.com
Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
Advanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel disease
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients
more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …
more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …
[HTML][HTML] Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection
Background & Aims Most patients with Crohn’s disease (CD) eventually require an intestinal
resection. However, CD frequently recurs after resection. We performed a randomized trial …
resection. However, CD frequently recurs after resection. We performed a randomized trial …
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease
…, E Dal Pont, V Di Leo, A Ferronato, W Fries… - International journal of …, 2007 - Springer
Background and aims Calprotectin and lactoferrin are specific neutrophil-derived proteins,
which can be measured in the feces because they are released by cells in inflammatory …
which can be measured in the feces because they are released by cells in inflammatory …
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study
…, OR Sociale, S Vetrano, W Fries… - Inflammatory bowel …, 2012 - academic.oup.com
Background Since immunomodulators and antitumor necrosis factor (TNF) agents are
increasingly used to treat inflammatory bowel disease (IBD), it is recommended to administer …
increasingly used to treat inflammatory bowel disease (IBD), it is recommended to administer …
[HTML][HTML] Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease
C Salvarani, W Fries - World journal of gastroenterology: WJG, 2009 - ncbi.nlm.nih.gov
Inflammation of axial and/or peripheral joints is one of the most frequent extra-intestinal
manifestations complicating the clinical course and therapeutic approach in inflammatory bowel …
manifestations complicating the clinical course and therapeutic approach in inflammatory bowel …
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3 …
…, B Freilich, K Friedenberg, W Fries… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier
phase 2 induction study, etrolizumab significantly improved clinical remission compared …
phase 2 induction study, etrolizumab significantly improved clinical remission compared …
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 …
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous
phase 2 induction study, etrolizumab significantly improved clinical remission versus …
phase 2 induction study, etrolizumab significantly improved clinical remission versus …
The histopathological approach to inflammatory bowel disease: a practice guide
…, G Becheanu, P Borralho Nunes, G Cathomas, W Fries… - Virchows Archiv, 2014 - Springer
Inflammatory bowel diseases (IBDs) are lifelong disorders predominantly present in
developed countries. In their pathogenesis, an interaction between genetic and environmental …
developed countries. In their pathogenesis, an interaction between genetic and environmental …